Advancing Psychedelic-Assisted Therapy in Missouri (MO-PAT): Innovation at the Speed of Safety.

Danielle R Adams, Torie Gettinger, Nathaniel Dell, Leopoldo J Cabassa, Ginger E Nicol

Abstract read

In one paragraph

Article in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Danielle R AdamsSchool of Social Work, College of Health Sciences, University of Missouri-Columbia, Columbia, Missouri.

Torie GettingerHealthy Mind Lab, Department of Psychiatry, Washington University, St. Louis, Missouri.

Nathaniel DellDepartment of Psychiatry, Washington University, St. Louis, Missouri.

Leopoldo J CabassaCenter for Mental Health Services Research, Brown School of Social Work, Washington University, St. Louis, Missouri.

Ginger E NicolHealthy Mind Lab, Department of Psychiatry, Washington University, St. Louis, Missouri.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The United States is facing a growing behavioral health crisis. Now more than ever, novel, safe and effective treatments are needed. Over the past decade, clinical trials of psychedelic-assisted psychotherapies (PAT) have shown promising results for treating a number of common behavioral health conditions with minimal adverse effects. This article provides a brief historical and sociopolitical context surrounding PAT, discusses unanswered questions related to the safety and quality of PAT, and charts a pathway forward through the complex policy, legal, and social barriers to uptake for the state of Missouri in its consideration of PAT as a behavioral health treatment. With careful consideration and proper infrastructure, PAT could represent a paradigm shift in how the field approaches the prevention, treatment, and potential recovery of behavioral health conditions. We outline how Missouri can be at the forefront of advancing the science and practice of PAT - cautiously.

Indexed as

HallucinogensHumansMental DisordersMissouriPsychotherapyHallucinogens

Identifiers

PMID39697578

PMCPMC11651254

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.